American Association for Cancer Research, Cancer Discovery, 7(3), p. 722-725, 2013
DOI: 10.1158/2159-8290.cd-13-0239
Full text: Download
Abstract Summary: Two studies published in this issue of Cancer Discovery describe the emerging mutational landscape of head and neck squamous cell carcinomas (HNSCC) and their genomic and epigenetic alterations, thus identifying novel actionable cancer drivers and predictive biomarkers for targeted therapies. Most genomic alterations in HNSCC converge in a handful of molecular pathways, resulting in cell-cycle deregulation, genomic instability, cell differentiation defects, and persistent mitogenic signaling, the latter involving aberrant phosphoinositide 3-kinase (PI3K)/mTOR pathway activation, thereby rendering HNSCC responsive to PI3K/mTOR inhibitors. Cancer Discov; 3(7); 722–5. ©2013 AACR. See related article by Lui et al., p. 761 See related article by Pickering et al., p. 770